Today, we are taking a look at the latest regarding noncirrhotic nonalcoholic steatohepatitis (NASH) in relation to clinical guidance, FDA approvals, and clinical trials. Due to recent nomenclature adjustments, today’s content includes both NASH and metabolic dysfunction-associated steatohepatitis (MASH) content along with and nonalcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated steatotic liver disease (MASLD) content, with MASH and MASLD being the preferred modernized terms.

Today, we are taking a look at the latest information regarding noncirrhotic NASH/MASH in relation to clinical guidance, FDA approvals, and ongoing clinical trials.

Current Clinical Guidance Related to Noncirrhotic Nonalcholic Steatohepatitis
Recent FDA Approvals Related to Noncirrhotic NASH/MASH

Below are medications recently approved by the FDA that we anticipate being incorporated into future clinical guidelines: 

Wegovy (semaglutide)

  • Novo Nordisk
  • August 2025
  • For the treatment of noncirrhotic metabolic dysfunction- associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults.

Rezdiffra (resmetirom)

  • Madrigal Pharmaceuticals
  • March 2024
  • Indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).
Ongoing Clinical Trials Related to Noncirrhotic NASH/MASH

The following are ongoing, Phase 3 clinical trials based in the United States that we anticipate may impact future clinical guidelines.

Check out our other content on hepatology-related topics. Sign up for alerts to keep up with the latest guidelines and insights.